New Market Study Published: Celltrion: Biosimilars Company Analysis

Sept. 12, 2012 - PRLog -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.

Scope
* Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
* Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.

Highlights

The company is thought to be responsible for filing the first biosimilar MAb for approval in Europe. In 2009, Celltrion signed an agreement to manufacture and co-market eight biosimilars with Hospira in the US, EU and other key markets. Hospira is a leader in injectable generics, representing a strong fit with biosimilars.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/449052_celltrion_biosimilars_c...
------------------------------------------------------------

Reasons to Get this Report

* Evaluate key products in Celltrion's biosimilar pipeline of seven monoclonal antibodies and one fusion protein
* With no sales capabilities and a limited international footprint, see how Celltrion is reliant upon partnerships for market access and sales

Report Table of Contents:

ABOUT THIS REPORT

* Chapter structure

* Executive summary
* Strategic insight
* Product analysis
* Operating performance
* Corporate structure

* Data sourcing

* Sales data

* PharmaVitae Explorer database

EXECUTIVE SUMMARY

* Celltrion biosimilars summary
* Celltrion biosimilars SWOT analysis

* Strengths
* Weaknesses
* Opportunities
* Threats

* Celltrion biosimilars infrastructure

STRATEGIC INSIGHT

* Celltrion to tap into monoclonal antibody market
* Celltrion to utilize marketing alliances

KEY PRODUCTS

* Overview
* Celltrion's biosimilar portfolio
* CT-P13 (infliximab)

* Overview
* Infliximab market size
* Key competitors
* Celltrion biosimilar development

* CT-P6 (trastuzumab)

* Overview
* Trastuzumab market size
* Key competitors
* Celltrion biosimilar development

* CT-P10 (rituximab)

* Overview
* Rituximab market sizing
* Key competitors
* Celltrion biosimilar development

* CT-P05 (etanercept)

* Overview
* Etanercept market sizing
* Key competitors

* CT-P15 (cetuximab)

* Overview
* Cetuximab market sizing
* Key competitors

* Other biosimilars in development

CORPORATE STRUCTURE

* Background
* Key corporate developments and M&A history
* Company structure

* The Celltrion Inc. and Celltrion Healthcare relationship

* Deals and alliances
* Recent developments

APPENDIX

* References

* Websites
* Datamonitor reports

* Exchange rates

TABLES

* Table: Celltrion - manufacturing and development metrics
* Table: Celltrion - biosimilar portfolio
* Table: Forecasted global Remicade sales, by region, ($m), 2011-16
* Table: Biosimilar infliximab drugs, 2012
* Table: Celltrion - biosimilar infliximab clinical trials
* Table: Forecasted global Herceptin sales, by region ($m), 2011-16
* Table: Biosimilar trastuzumab drugs, 2012
* Table: Celltrion - biosimilar trastuzumab clinical trials
* Table: Forecasted global MabThera/Rituxan sales, by region ($m), 2011-16
* Table: Pipeline and marketed biosimilar/copy-biologic rituximab drugs
* Table: Celltrion - biosimilar rituximab clinical trials
* Table: Forecasted global Enbrel sales, by region ($m), 2011-16
* Table: Biosimilar/copy-biologic etanercept drugs, 2012
* Table: Forecasted global Erbitux sales, by region ($m), 2011-16
* Table: Biosimilar/copy-biologic cetuximab drugs, 2012
* Table: Celltrion - biosimilar portfolio
* Table: Celltrion - biosimilar deals
* Table: Exchange rates, 2011

FIGURES

* Figure: The PharmaVitae Explorer
* Figure: Celltrion biosimilars overview
* Figure: Celltrion SWOT analysis
* Figure: MAb sales that Celltrion is targeting, 2011-16
* Figure: Celltrion geographical deal coverage
* Figure: Celltrion company structure

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.